MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Opicapone management: A 2-year follow up real- life practice study

M. Mata, C. Borrue, M. Almarcha (Madrid, Spain)

Meeting: MDS Virtual Congress 2020

Abstract Number: 1036

Keywords: COMT inhibitors, Pharmacotherapy, Wearing-off fluctuations

Category: Parkinson’s Disease: Pharmacology and Therapy

Objective: The aim of this work is to show our clinical experience with opicapone in real practice in a cohort of 68 parkinsonian patients followed 2 years.

Background: Opicapone is a three-generation, long-action, peripheric, selective and reversible COMT-I, that has shown efficacy treating “wearing- OFF” in idiopathic Parkinson´s disease (PD) (1).
Follow-up in pivotal studies is 6-months, and long-term experience in real life is still lacking.

Method: Retrospective study of parkinsonian patients treated with opicapone in a Movement Disorders Unit, from June 2017 to June 2019.
We have analyzed demographic characteristics, disease stage, withdrawn reasons, and mean time to new dopaminergic therapy dose increase.

Results: Demographic characteristics of the cohort and main results are shown on the table below.
We needed to decrease the levodopa dose in 47% of the patients, with a mean reduction of 30% of the dose.
We have identified that patients at II-III H-Y stages, suboptimal response and simple motor fluctuations are the best responders and shown greatest benefit. 14 patients have fluctuations of less than 2 years of evolution (Early Fluctuators)
We had to discontinue opicapone in 35% of the patients, mostly in the first year of follow -up. Causes of withdrawal are shown on the Figure.
The incidence of dyskinesia was lower in our cohort than in the pivotal studies.
In 13% of the patients, the clinical benefits lasted more than 8 months. Two patients no needed to increase levodopa dose in the 12 months after introduction of opicapone.

Conclusion: Opicapona was effective and well tolerated in PD patients at II-III H-Y stages, in some cases with a prolonged benefit effect over time.
In our experience, opicapone should be administered with caution and close monitoring in advanced PD patients or cognitive impairment. A higher risk of confusional state and hallucinations were seen in such population.

TABLE

Figure

References: (1) Ferreira J et al. Lancet Neurol 2016; 15: 154-165

To cite this abstract in AMA style:

M. Mata, C. Borrue, M. Almarcha. Opicapone management: A 2-year follow up real- life practice study [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/opicapone-management-a-2-year-follow-up-real-life-practice-study/. Accessed May 15, 2025.
  • Tweet
  • Email
  • Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/opicapone-management-a-2-year-follow-up-real-life-practice-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
  • #26133 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley